Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$482.00 | Nrf | Cqdlznbg |
Eli Lilly: Detailed Phase 3 Alzheimer's Data With Donanemab Reinforces Drug's Strong Outlook
Eli Lilly revealed details of the positive phase 3 Alzheimer’s study Trailblazer-ALZ 2 with donanemab that are largely in line with our expectations. We are not making any major changes to our outlook for donanemab or Eli Lilly’s fair value estimate. However, the strong data helps to reinforce the firm’s wide moat, building on an innovative pipeline of next-generation drugs.